2-(4-amino-5-methyl-pyrazol-1-yl)-2-methylpropanamide | 1536200-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-amino-5-methyl-pyrazol-1-yl)-2-methylpropanamide
• 英文别名: 2-(4-amino-5-methyl-1H-pyrazol-1-yl)-2-methylpropanamide；2-(4-Amino-5-methylpyrazol-1-yl)-2-methylpropanamide
• CAS: 1536200-61-9
• 化学式: C₈H₁₄N₄O
• 分子量: 182.225
• InChiKey: ZMZUKEHUOKTMOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-amino-5-methyl-pyrazol-1-yl)-2-methylpropanamide 在 三氟乙酸 、 三氯氧磷 作用下， 以 乙二醇甲醚 为溶剂， 反应 1.5h， 生成 2-methyl-2-(5-methyl-4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)propanenitrile
  参考文献：
  名称：

  Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

  摘要：

  Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is one of the most compelling targets for a potential disease-modifying Parkinson's disease therapy. Herein, we disclose structurally diverse small molecule inhibitors suitable for assessing the implications of sustained in vivo LARK2 inhibition. Using previously reported aminopyrazole 2 as a lead molecule, we were able to engineer structural modifications in the solvent-exposed region of the ATP-binding site that significantly improve human hepatocyte stability, rat free brain exposure, and CYP inhibition and induction liabilities. Disciplined application of established optimal CNS design parameters culminated in the rapid identification of GNE-0877 (11) and GNE-9605 (20) as highly potent and selective LRRK2 inhibitors. The demonstrated metabolic stability, brain penetration across multiple species, and selectivity of these inhibitors support their use in preclinical efficacy and safety studies.

  DOI：

  10.1021/jm401654j
• 作为产物：
  描述：

  ethyl 2-methyl-2-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanoate 在 ammonium hydroxide 、 草酰氯 、 palladium on activated charcoal 、 氢气 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 21.2h， 生成 2-(4-amino-5-methyl-pyrazol-1-yl)-2-methylpropanamide
  参考文献：
  名称：

  [EN] COMPOUNDS
  [FR] COMPOSÉS

  摘要：

  本发明涉及抑制LRRK2激酶活性的新化合物，其制备方法，含有它们的组合物，以及它们在治疗或预防由LRRK2激酶活性特征的疾病中的应用，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。

  公开号：

  WO2015113452A1

文献信息

• Compounds as LRRK2 kinase inhibitors
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US10087186B2

  公开（公告）日：2018-10-02

  The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  本发明涉及抑制 LRRK2 激酶活性的新型化合物、其制备工艺、含有这些化合物的组合物以及它们在治疗或预防以 LRRK2 激酶活性为特征的疾病（例如帕金森病、阿尔茨海默病和肌萎缩性脊髓侧索硬化症（ALS））中的用途。
• LRRK2 inhibitors for the treatment of Parkinson's disease
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10618901B2

  公开（公告）日：2020-04-14

  The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  本发明涉及抑制 LRRK2 激酶活性的新型化合物、其制备工艺、含有这些化合物的组合物以及它们在治疗或预防以 LRRK2 激酶活性为特征的疾病（例如帕金森病、阿尔茨海默病和肌萎缩性脊髓侧索硬化症（ALS））中的用途。
• COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3099695A1

  公开（公告）日：2016-12-07